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female; 48% control patients. Overall, 15.8% of patients experienced hyperkalemia: 
9.8% had ≥ 1 mild hyperkalemia event and 6.1% had moderate/severe events. 8.5% of 
control patients experienced hyperkalemia events compared with 23.5% of patients 
with HF, 29.5% of patients with CKD stages 3-4, and 47.6% of patients with HF and 
CKD stages 3-4. Hyperkalemia was more prevalent in patients with each measured 
comorbidity compared to control patients, and its severity increased with CKD sever-
ity (all comparisons, P< 0.0001). Moderate/severe hyperkalemia was more prevalent in 
patients with later-stage CKD compared to patients with earlier stage kidney disease. 
Prevalence of hyperkalemia was generally higher in patients aged ≥ 65 years than in 
similarly comorbid patients aged < 65 years. ConClusions: A retrospective analysis 
of electronic medical record data demonstrated that hyperkalemia was more common 
in patients with HF and/or CKD —especially in those with more advanced disease—
than in patients without these comorbidities.
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Venous Thromboembolism PreValenCe in FrenCh and us hosPiTals: 
ComParison on The basis oF The naTional daTa bases
Allaert F.1, Quantin C.2, Benzenine M.2
1Medical evaluation Chair ESC Dijon, Dijon, France, 2university hospital Dijon, Dijon, France
objeCtives: describe the national prevalence of deep vein thrombosis (DVT) and 
pulmonary embolism (PE), among patients hospitalized in private and public French 
hospitals and to compare it to those described in US Hospitals. Methods: The 
statistics are from the national PMSI MCO databases inspired by the US Medicare 
system. Data are encoded using ICD10. The codes used for VTE are I801 to I809 
for DVT and codes I260, I269 for PE. The analyses identify all VTE, DVT without PE 
(DVT) and PE with or without previous/associated DVT. The study data cover the 
period 2005 to 2011. The French data are compared to those issued in the Morbidity, 
Mortality Weekly Report of the Centre for Disease Control and Prevention. Results: 
Data from the national database reveal that over the period 2005 to 2011 the inci-
dence of hospital stays came to 860 343 (1.09%) for VTE, with 428 261 (0.543%) for 
DVT without PE and 432 082 (0.548%) for PE. The mean number of VTE hospitalized 
per year over the period was 122 906, including 61 180 for DVT and 61 726 for PE. 
Out of the French population > 18y, those 122 906 VTE correspond to an incidence of 
247 hospitalizations for 100 000 vs. 239 in the USA for the VTE, of 124 vs. 118 for the 
DVT without EP and of 123 vs. 121 for the EP which is very similar. These instances 
of VTE occurred in France for 43.4% in men vs. 45.8% in the USA and 56.6% vs. 
54.2% in women. ConClusions: French VTE incidence is high and similar to those 
described in the USA. These results point out an alarming situation that questions 
the quality of prevention and/or its effectiveness. VTE prevention policies must 
be strengthened in hospitals for the sake of patients and healthcare savings alike.
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The PreValenCe and odds-raTios oF selF-rePorTed diagnosis 
oF hyPerTension among us adulTs by raCial/eThniC subgrouPs, 
examining The JoinT eFFeCT oF mulTiPle risk FaCTors: naTional 
healTh inTerView surVey, 2004 - 2013
Godwin O., Brown L.M.
Chapman University, Irvine, CA, USA
objeCtives: The differences in prevalence and odds ratios of self-reported hyper-
tension among racial/ethnic groups in the United States have not been fully 
explained. This current study focused on investigating the prevalence and the joint 
effect of multiple risk factors on self-reported hypertension in the United States 
ethnic subgroups. Methods: A cross-sectional study design was used to determine 
the prevalence of self-reported hypertension among non-Hispanic whites, non-
Hispanic blacks, and Hispanics in the National Health Interview Survey (NHIS), 2004 
– 2013. An estimated total of 607 million cases of self-reported hypertension among 
United States adults 18 years or older was identified. Logistic regression models 
were utilized to estimate the odds ratios (OR) and 95% confidence intervals for the 
selected risk factors associated with hypertension. Results: The overall prevalence 
of self-reported hypertension in the non-Hispanic whites, non-Hispanic blacks, and 
Hispanics was 29.4%, 35.4%, and 19.5% respectively. After adjusting for the selected 
risk factors , a subgroup analysis of subjects aged 18-44 years non-Hispanic black 
males and females were found to have statistically significant lower odds of self-
reporting hypertension compared to non-Hispanic whites (adjusted odds ratios 
(AOR), 0.62; 95% CI, 0.57-0.66; P < 0.01 males; AOR, 0.62; 95% CI, 0.58-0.66; P < 0.01 
females, respectively). In contrast, non-Hispanic blacks aged 45 to 64 years (AOR, 
1.42; 95% CI, 1.33-1.53; P < 0.01 males; AOR, 2.39; 95% CI, 2.24-2.54; P < 0.01 females, 
respectively) had statistically significant higher odds of self-reporting hypertension 
compared to non-Hispanic whites aged 45 to 64 years. ConClusions: This result 
challenges the commonly held belief that all blacks have a higher prevalence of 
hypertension, and underscores the need for data segmentation to further deter-
mine with more precision the age at which non-Hispanic blacks shift from being 
less likely to self-reporting hypertension to more likely than non-Hispanic whites.
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geograPhiC diFFerenCes in aVailabiliTy oF anTihyPerTensiVe 
mediCaTions: a ComParison oF ausTralia, Canada, saudi arabia, uk, 
and The us
Almutairi H.1, Alzarea A.I.1, Seoane-Vazquez E.1, Mekary R.2
1MCPHS University, Boston, MA, USA, 2MCPHS University, N/A, MA, USA
objeCtives: To compare the number of antihypertensive medications that were 
approved by the US Food and Drug Administration, the UK Medicines and Healthcare 
Products Regulatory Agency, the Australian Therapeutic Goods Administration, 
Health Canada, and the Saudi Food & Drug Authority as of [2014]. Methods: 
Antihypertensive medications information was collected from the websites of the 
agencies. Hypertension prevalence by country was collected from the WHO website. 
Descriptive analysis was conducted in the study. Spearman correlation was used 
to estimate the correlation between the number of approvals and hypertension 
prevalence. SAS version 9.3 was used in the analysis. Results: The prevalence 
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Trends in anTihyPerTensiVe mediCaTion use in us oFFiCe-based 
PraCTiCes: are elderly PaTienTs TreaTed diFFrerenTly?
Gu A.1, Yue Y.2, Argulian E.3
1St. John’s University, Jamaica, NY, USA, 2Baruch College/CUNY, New York, NY, USA, 3Mount Sinai 
St. Luke’s Hospital, New York, NY, USA
objeCtives: 1) To investigate recent trends in antihypertensive medication pre-
scribing among US adults with hypertension in office-based practices; 2) To deter-
mine if there are differences in the classes of antihypertensive agents prescribed for 
the elderly population as compared with younger patients. Methods: The latest 
available National Ambulatory Medical Care Survey (NAMCS) (2003 – 2010) were ana-
lyzed. All encounters with ICD-9 codes for essential hypertension (eg, 401.0, 401.1, 
or 401.9) and patients aged ≥ 18 years were identified. Multivariate logistic regres-
sion analyses determined the adjusted associations between age (< 60 years, ≥ 60 
years) and the prescription use of antihypertensive classes, as well as prescribing 
year trend. Variance estimates were computed with the Taylor series linearization 
approximation. Results: Approximately 674 million weighted office visits were 
included in the analysis. Overall, the prescription of antihypertensive medication 
increased from 69.2% in 2003 to 2004 to 78.8% in 2009 to 2010 (P trend< 0.01) and 
the upward trend was consistent in both age groups. This was accompanied by an 
improvement in the overall hypertension control (from 39.6% to 49.3%, P trend< 0.01). 
The proportions of visits with β -blocker (from 25.4% to 34.7%, P trend< 0.01) and 
angiotensin receptor blocker (ARB) prescriptions (from 17.0% to 22.1%, P trend= 0.02) 
increased for older patients. Prescribing rates for diuretics, β -blockers, and calcium-
channel blockers (CCBs) were significantly higher among patients aged ≥ 60 years 
compared to their younger counterparts, while rates for ARBs and angiotensin-
converting enzymes (ACEIs) were relatively comparable between the two groups. 
The increase in use of β -blockers in older patients persisted after excluding patients 
with congestive heart failure and ischemic heart disease. ConClusions: In office-
based practices, antihypertensive medication prescribing among US adults with 
hypertension increased significantly in recent years which was accompanied by 
some improvement in hypertension control. The prescribing patterns differed 
among younger and older patients but continuous use of β -blockers without other 
compelling indications raises concerns.
PCV32
ComParison oF diFFerenT meTaboliC syndrome CriTeria and 
indiVidual risk FaCTors in The risk PrediCTion oF CardioVasCular 
and ChroniC diseases
Bhounsule P., Peterson A.M.
University of the Sciences in Philadelphia, Philadelphia, PA, USA
objeCtives: (1) To compare risks posed by the metabolic syndrome (MetS) diagnosed 
with four different criteria and cardiovascular risk factors in the development of 
diabetes mellitus 2 (T2D), cardiovascular disorders and other chronic disorders. (2) To 
determine if modification should be made to existing MetS definitions and standards 
of diagnosis of high risk patients. Methods: A combination of NHANES 2009-2010 
and 2010-2011 databases formed our study cohort. MetS criteria included harmo-
nized 2009 World Health Organization definition, criteria from National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III), International Diabetes 
Federation (IDF) and European Group for Study of Insulin Resistance (EGIR). Individual 
cardiovascular risk factors included smoking, alcoholism, albuminurea, elevated 
C-reactive protein levels and heredity of diabetes and cardiovascular disorders. Risk 
prediction was carried out for chronic disorders such as diabetes, cardiovascular dis-
orders, arthritis, asthma, emphysema, bronchitis, cancer and AIDs. Adjusted relative 
risk (RRs) using Poisson regression was calculated for each criteria and individual risk 
factors. Results: MetS failed to predict risk for cardiovascular disorders. However 
albuminurea (RR= 2.25), smoking (RR= 2.16) and heredity (RR= 1.52) posed a risk for 
cardiovascular disorders. All except smoking (0.32) demonstrated high risk for asthma. 
Smoking (RR= 4.15) along with all the MetS criteria (RR with WHO= 2.63; NCEP= 3.16; 
IDF= 5.67) except European criteria (RR= 0.67) predicted risk for emphysema. MetS 
(RR with WHO= 2.24; Europe= 5.43; NCEP= 3.31; IDF= 2.66) and albuminurea (RR= 1.49) 
were good predictors of kidney conditions. Similarly MetS (RR with WHO= 3.67; 
Europe= 6.33; NCEP= 4.24; IDF= 1.89), albuminurea (RR= 2.94), alcoholism (RR= 3.08) and 
heredity (RR= 3.74) were associated with risk for liver conditions. No MetS criteria and 
individual risk factors showed an association with risk for AIDS. ConClusions: 
Overall European MetS criteria emerged as the strongest risk predictor for chronic 
conditions. The RRs of individual risk factors depict significant chronic disease pre-
dicting ability. Recommendations may be made to policy makers to alter or make 
additions to the current MetS definition.
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hyPerkalemia is highly PreValenT in PaTienTs wiTh Cardiorenal 
ComorbidiTies ComPared To PaTienTs wiThouT These ComorbidiTies
Latts L.M.1, Reaven N.L.2, Funk S.E.2, McGaughey K.J.3, Adamson R.T.4
1LML Health Solutions LLC, Denver, CO, USA, 2Strategic Health Resources, La Canada, CA, USA, 
3California Polytechnic State University, San Luis Obispo, CA, USA, 4Barnabas Health, West 
Orange, NJ, USA
objeCtives: To investigate the prevalence of hyperkalemia in patients with chronic 
kidney disease (CKD) or heart failure (HF). Methods: De-identified medical records 
(2007-2012) from a US population aged ≥ 5 years with ≥ 2 potassium (K+) readings were 
evaluated. Inclusion criteria: ≥ 1 K+ value between 2.5 and 10 mEq/L during 2008 to 
2012. Exclusion criteria: acute kidney injury (AKI). Hyperkalemia was classified as mild 
(K+ 5.1 to 5.4 mEq/L) or moderate/severe (K+ ≥ 5.5 mEq/L) based on patient’s highest 
measured value. Patient comorbidities were assessed: CKD by stage, end-stage renal 
disease (ESRD), HF, diabetes, and disease combinations. Control patients had no CKD 
stage 2+, ESRD, HF, diabetes or AKI. Chi-square tests assessed whether prevalence of 
hyperkalemia differed significantly between control patients and those with comor-
bidities. Hyperkalemia prevalence was also compared by age group (< 65 years vs 
≥ 65 years). Results: 1,636,337 patients were evaluated; mean age, 56 years; 56% 
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objeCtives: This study aimed to investigate the correlation between cardiovascular 
(CV) health and CV disease knowledge of Life’s Simple 7 (LS7) among 3 age groups in 
Hong Kong – young adults, middle aged, and the elderly. Methods: Young adults 
and middle-aged adults were identified from the on-campus health check at the 
Chinese University of Hong Kong. Elderly subjects were recruited from the com-
munity outreach in 15 community elderly centers. The subjects’ demographics, 
lifestyle behavior and risk knowledge were obtained through a validated question-
naire. The body mass index, random capillary blood glucose, blood cholesterol and 
blood pressure were measured during the on-campus health check and community 
outreach sessions. LS7 score and risk knowledge score for each subject were calcu-
lated. Logistic regression was used to estimate the odd ration and 95% confidence 
intervals for the demographic characteristics on LS7 and knowledge. Results: A 
total of 996 subjects were included in this study (mean age: 56.3 ± 25.5 years old; 28% 
male). There were only 0.6% subjects had ideal CV health while 35.9% had 5 to 7 ideal 
CV health metrics. Subjects ≥ 65 years (OR 2.341, 95% CI 1.779-3.080, P < 0.0005) and 
subjects with tertiary education or above (OR 2.031, 95% CI 1.527-2.701, P < 0.0005) 
were more likely to obtain optimum LS7 (scoring ≥ 10 out of 14 in LS7 score). Subjects 
≤ 65 years (OR 1.695, 95% CI 1.297-2.215, P < 0.0005) and those with tertiary education 
or above (OR 1.859, 95% CI 1.412-2.448, P < 0.0005) were more likely to obtain full CV 
disease risk knowledge score. No association was found between having optimum 
LS7 and full CV knowledge. ConClusions: Less than 1% of adults in this study 
population had ideal CV health as defined by AHA. Knowledge has no association 
but young age and tertiary education had positive association with CV health.
PCV40
FaCTors ThaT negaTiVely inFluenCe The PrediCTion oF warFarin 
sTable dose when emPloying a genoTyPe-guided aPProaCh
Lee W.1, Chumnumwat S.1, Duarte J.1, Gratie D.1, Galanter W.L.1, Walton S.M.1, Krishnan J.A.1, 
Bauman J.L.1, Cavallari L.H.2, Nutescu E.A.1
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Florida, Gainesville, FL, USA
objeCtives: Genotype-guided therapy has been demonstrated to enhance the accu-
racy of warfarin dosing. However, factors that limit the predictive accuracy of this 
approach have not been evaluated in a heterogeneous population. This study identi-
fied patient characteristics and clinical factors that contributed to poor prediction of 
a warfarin therapeutic dose when using a genotyped-guided approach. Methods: 
This was a prospective observational study of patients managed by the University of 
Illinois Hospital and Health Sciences System Pharmacogenetics Service who have 
attained a warfarin therapeutic dose. The primary outcome was a large dose devia-
tion (> 20%) between the genotype-guided predicted dose and the actual warfarin 
therapeutic dose. Variables examined included patient demographics, interacting 
medications, comorbidities, genotype information, baseline international normal-
ized ratio, and reason for anticoagulation. Multivariate logistic regression was used 
to estimate the odds ratio (OR) for a large dose deviation. Results: Of the 146 
consecutive patients enrolled, 23.3% were Hispanics, 54.1% were African American, 
and the mean age was 54.2±17.9 years. Fifty-three percent of the study cohort had a 
large dose deviation. After adjusting for potential confounders, being middle aged 
(41-65 vs. 18-40 years) and Hispanic (vs. Whites and Asians) had a 4.15-fold (95%CI 
1.24-13.95, p= 0.021) and 7.58-fold (95%CI 1.69-33.93, p= 0.008) increased odds for 
a large dose deviation, respectively. Patients who took warfarin for thrombosis 
prophylaxis versus treatment were 3.2-fold more likely to have a large dose devia-
tion (95%CI 1.14-8.99, p= 0.027). In addition, patients who required a high warfarin 
maintenance dose (> 7.5mg/day) versus average dose (3-7.5 mg/day) were at an 
elevated risk (adjusted OR 5.21, 95%CI 1.30-20.78, p= 0.019) of having a large dose 
deviation. ConClusions: Our results highlight factors that might contribute to 
poor prediction of warfarin dosing using a genotype-guided approach and sug-
gest that methods to refine dose prediction are needed for under-studied patient 
populations, including Hispanics and patients receiving warfarin for thrombosis 
prophylaxis.
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examining assoCiaTion beTween liVer enzymes and liPid leVels 
amongsT adulTs in The uniTed sTaTes: a Cross seCTional sTudy
Sakharkar P., Deb S.
Roosevelt University College of Pharmacy, Schaumburg, IL, USA
objeCtives: Elevated low density lipoprotein cholesterol (LDL-C) and low high 
density lipoprotein cholesterol (HDL-C) level is a characteristic of dyslipidemia. 
Increase in blood lipids levels has the potential to cause hepatic disorders such as 
non-alcoholic fatty liver disease and liver cirrhosis. The goal of this study was to 
examine the association between liver enzymes and lipid levels amongst adults 
in the United States. Methods: The National Health and Nutrition Examination 
Survey (NHANES) data from 2005 to 2006 was used to examine the association 
between liver enzymes and lipid levels amongst adults in the United States. Data 
were analyzed for descriptive statistics and for differences using the t-test, Chi 
square test and ANOVA. A regression analysis was performed to identify relation-
ships between demographic characteristics, liver enzymes and lipid levels. A p value 
of < 0.05 was considered statistically significant. Results: A total of 2,201 adults 
(20 yrs. and above) were included in this study. Sample mean age was 48 ± 19 yrs. 
Thirty eight percent adults had LDL-C levels greater than 130mg/dL and 14% had 
HDL-C levels greater than 60mg/dL according to National Cholesterol Education 
Program - Adult Treatment Panel (NCEP-ATP III) guidelines. A significant relation-
ship was observed between HDL-C and alkaline phosphotase levels (ALP), LDL-C 
and asparatate aminotransferase (AST), triglycerides and AST levels (p< 0.05). Adults 
with LDL-C > 100mg/dL were associated with two times higher odds of abnormal 
AST levels (95%CI:1.5–2.8, p< 0.001), whereas, HDL-C levels < 60 mg/dL were associ-
ated with 2.9 times higher odds of abnormal AST levels (95%CI:2.2–3.7, p< 0.001). 
Regression analysis showed significant relationship between LDL-C, HDL-C, tri-
glycerides, ALT, AST, ALP and age (p< 0.05). ConClusions: There was significant 
association between abnormal asparatate aminotransferase and low HDL-C levels, 
even though low HDL-C levels are desirable to reduce cardiovascular risks. There 
of hypertension in 2008 varied by country (US= 15.6%, UK= 23.4%, Australia= 18.2%, 
Canada= 15.3%, and Saudi Arabia= 31.2%). There were 138 antihypertensive medica-
tions and 61 combinations available in all five countries. The US had the highest 
number of antihypertensive medications (70.0%), followed by Canada (56.5%), UK 
(52.8%), Australia (51.44%) and Saudi Arabia (49.2%). There were 31 combinations 
of antihypertensive medications with the FDA listing 50.8% of those combinations, 
followed by the UK (40.9%), Saudi Arabia and Australia (both 37.7%), and Canada 
(34.4%).The therapeutic classes with the larger number of approvals were beta 
blockers (n= 14), angiotensin-converting enzyme inhibitors (n= 11) and thiazide 
diuretics (n= 11). The relationship between the number of antihypertensive drugs 
approved and hypertension prevalence appeared inverse, (Spearman correlation 
coefficient= -0.8), yet non-significant (P= 0.10), most likely due to lack of power 
(n= 5) and the ecological nature of this correlation. ConClusions: Differences exist 
in the number of antihypertensive medications and therapeutic classes available 
in each country. The US had the highest access to antihypertensive medications 
among the countries included in the study. Further studies are needed to assess 
the utilization of antihypertensive medications and the potential relationship with 
hypertension prevalence.
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a reTrosPeCTiVe daTabase sTudy To inVesTigaTe The morbidiTy and 
PharmaCeuTiCal inTerVenTion oF Pulmonary arTerial hyPerTension 
in JaPan
Sawachi S.
Pfizer Japan Inc., Tokyo, Japan
objeCtives: Although the number of patients with PAH who were certified as 
patients of Specified Rare and Intractable Diseases is annually provided by the 
Ministry of Health, Labor and Welfare (MHLW) in Japan, the morbidity rate and 
treatment situation for PAH has not been clearly investigated yet. This study aimed 
to investigate morbidity rate of PAH using a Japanese healthcare database. The 
pharmaceutical intervention for PAH was also investigated among those with 
PAH. Methods: The Japanese healthcare database which contains approximately 
2.1 million subjects covered by employment-based health insurance (MinaCare Co. 
Ltd) was used for this study. The patients with PAH who were newly diagnosed 
as Pulmonary Hypertension (PH) between September 1, 2011 and August 31, 2012 
and prescribed at least 1 anti-PAH drug was extracted. The patients with PH were 
identified by using International Classification of Diseases (ICD)-10 codes (I270, I271, 
I272, I278, I279 and P293) or by free formatdiagnosis name including “Pulmonary 
Hypertension”. Results: Of approximately 1.1 million person-years of observation, 
34 were identified as newly diagnosed PAH patients. Therefore, the crude rate of PAH 
morbidity was 30.4 per 1,000,000 person-years. The commonly used medication as 
the first treatment among these 34 patients were Beraprost(70.6%), Sildenafil(20.6%), 
Tadalafil(5.9%) and Bosentan(5.9%). ConClusions: This is the first report to show 
the morbidity rate of PAH in Japan. This study revealed that Beraprost was the most 
commonly used first PAH treatment agent in Japan in the real-world data setting, 
although Sildenafil and Bosentan are recommended to be used as the 1st line treat-
ment in the Guideline for “Treatment of Pulmonary Hypertension” (JCS2012). In 
order to improve the quality of PAH treatment and the patients’ outcome, it is highly 
important to increase awareness of the recommended treatment and fill the gap 
between the guideline and actual clinical use of these drugs.
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inCreased risk oF arrhyThmia in PaTienTs wiTh Psoriasis: a maTChed 
CohorT sTudy
Chang W.1, Chiu H.2, Huang W.1, Wen Y.3, Tsai Y.1, Tsai T.2
1National Yang Ming University, Taipei, Taiwan, 2National Taiwan University Hospital, Taipei, 
Taiwan, 3Chang Gung University, Taoyuan, Taiwan
objeCtives: Inflammation contributes to the pathogenesis of both psoriasis 
and arrhythmia, and psoriasis has been shown to be associated with substantial 
cardiovascular morbidity and mortality. On the other hand, however, only a few 
small studies have investigated the risk of arrhythmia in psoriasis. The aim of this 
study was to determine whether patients with psoriasis have an increased risk of 
arrhythmia. Methods: A retrospective, population-based matched cohort study 
of patients with psoriasis was conducted from January 1, 2003, to December 31, 
2011. New-onset psoriasis patients (n= 40637) and psoriasis-free matched controls 
(n= 162548) were followed, with a mean follow-up of 6.41 years. Diagnoses and 
prescriptions of the patients were obtained from the National Health Insurance 
Research Database (NHIRD), Taiwan. Patients with psoriasis were classified as severe 
if they received a systemic antipsoriatic therapy and/or phototherapy or otherwise, 
mild. Risk of arrhythmia was analyzed by using a multivariable Cox proportional 
hazards regression model. Results: There were 3910 arrhythmia (9.62%) within the 
psoriasis patients and 11612 (7.14%) arrhythmia within the comparison subjects, 
and the incidences per 100000 person-years were 1541.37 and 1106.09, respectively. 
After adjusted for comorbidities and medications, the incidence risk of arrhythmia 
was increased in all groups of psoriasis patients compared to the controls. The 
adjusted hazard ratios (95% confidence intervals) for arrhythmia were 1.30 (1.25 to 
1.35), 1.31 (1.25 to 1.36), 1.21 (1.09 to 1.34), 1.37(1.16 to 1.62) and 1.29 (1.24-1.34) in the 
overall, mild, severe psoriasis, psoriasis patient with psoriatic arthritis (PsA), and 
psoriasis patients without PsA (PsC), respectively. ConClusions: Patients with 
psoriasis have a higher risk of developing arrhythmia, independent of traditional 
cardiovascular risk factors. Moreover, the risk of arrhythmia in PsA was higher than 
PsC. Increased awareness of the arrhythmia risk in the cardiovascular assessment 
in psoriasis patients is recommended.
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liFe’s simPle 7 and CardioVasCular disease risk knowledge in hong 
kong
Lee V., Kong K.Y., Fong F., Ngai L., Wong V., Yan B.P.
Chinese University of Hong Kong, Shatin, Hong Kong
